A5080695903- Biosimilars and Bioanalytical Methods
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Advanced Biosensing Techniques and Applications
- Chronic Lymphocytic Leukemia Research
- Sarcoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- Monoclonal and Polyclonal Antibodies Research
- Biomedical and Engineering Education
- Protein purification and stability
Takeda (United States)
2016-2025
Millennium Engineering and Integration (United States)
2017-2018
AstraZeneca (United States)
2017
The 14th edition of the Workshop on Recent Issues in Bioanalysis (14th WRIB) was held virtually June 15-29, 2020 with an attendance over 1000 representatives from pharmaceutical/biopharmaceutical companies, biotechnology contract research organizations, and regulatory agencies worldwide. WRIB included three Main Workshops, seven Specialized Workshops that together spanned 11 days order to allow exhaustive thorough coverage all major issues bioanalysis, biomarkers, immunogenicity, gene...
The 17th Workshop on Recent Issues in Bioanalysis (17th WRIB) took place Orlando, FL, USA June 19–23, 2023. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned 1 week allow an exhaustive thorough coverage all major issues bioanalysis biomarkers, immunogenicity, gene therapy, cell therapy vaccines....
The 18th Workshop on Recent Issues in Bioanalysis (18th WRIB) took place San Antonio, TX, USA May 6-10, 2024. Over 1100 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned 1 week allow an exhaustive thorough coverage all major issues bioanalysis biomarkers, immunogenicity, gene therapy, cell therapy...
Bacterial and synthetic DNAs containing CpG dinucleotides in specific sequence contexts (CpG DNA) activate the vertebrate immune system produce potent Th1 responses. Recently, we reported immunomodulatory oligonucleotides (IMOs) 3'-3'-attached novel structures (immunomers) immunostimulatory CpR (R=2'-deoxy-7-deazguanosine) show stimulatory activity with distinct cytokine secretion profiles. In present study, evaluated vivo immunopharmacological antitumor properties of second-generation...
Introduction: Despite high overall 5-year survival rates for childhood HL and sALCL, improved options are needed patients (pts) who do not respond to, or relapse following, initial therapy. This phase 1/2 open-label, dose-escalation trial (NCT01492088) evaluated the safety, PK, antitumor activity of antibody-drug conjugate, brentuximab vedotin (BV), in pediatric pts with R/R sALCL whom treatment alternatives exist. Methods: BV was administered by intravenous infusion once every 21 days up to...